Log in to search using one of your social media accounts:


Corynebacterium, Kingella Abundance Tied to HNSCC Risk

No correlation for overall microbiome composition with risk of head and neck squamous cell carcinoma
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Oncology, ENT, Pathology, Journal, Source Type: news

Related Links:

miR-375 inhibits IFN-γ-induced programmed death 1 ligand 1 surface expression in head and neck squamous cell carcinoma cells by blocking JAK2/STAT1 signaling. Oncol Rep. 2018 Jan 02;: Authors: Wu Q, Zhao Y, Sun Y, Yan X, Wang P Abstract Upregulation of programmed death 1 ligand 1 (PD-L1) in cancer cells and its ligation to PD-1 on T cells facilitates cancer cell escape from immune surveillance. Therapies with PD-1 or PD-L1 antibodies have resulted in marked clinical responses in various cancer types. Hence, modulators that inhibit PD-L1 expression in cancer cells may serve as a nov...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Abstract Enthusiasm for the use of dietary bioactive compounds as chemopreventive agents and adjuvants for current therapies has increased laboratory research conducted on several types of cancers including Head and Neck Squamous Cell Carcinoma (HNSCC). The green chemoprevention movement is a modern approach to highlight healthy lifestyle changes that aim to decrease the incidence of HNSCC. A healthy diet can be an effective way to prevent the development of oral cancers. Discovery of the naturally occurring plant based compounds called phytochemicals has facilitated the development of new treatment strategies for...
Source: Current Topics in Medicinal Chemistry - Category: Chemistry Authors: Tags: Curr Top Med Chem Source Type: research
BACKGROUNDTime to treatment initiation (TTI) is increasing and is associated with worsening survival. In the current study, the authors sought to identify a mechanism for this relationship by assessing the effect of TTI on clinical‐to‐pathologic upstaging in patients with head and neck squamous cell carcinoma (HNSCC). METHODSUsing the National Cancer Data Base, the authors analyzed patients receiving definitive surgery for SCC of the oral cavity, oropharynx, larynx, and hypopharynx from 2005 through 2014. The primary outcome was T, N, or stage group upstaging, defined as higher pathologic stage than clinical stage. TTI...
Source: Cancer - Category: Cancer & Oncology Authors: Tags: Original Article Source Type: research
ConclusionPCI cell lines showed higher resistance to dose-dependent reduction in cell number, proliferation, and protection from apoptosis compared to NHF and HDMEC. In parallel, we observed a high basic and radiation-induced expression of intracellular HSP70 leading to the assumption that the radioresistance of PCI cells is conferred by HSP70.Clinical relevanceHNSCC use HSP to escape radiation-induced apoptosis and certain subtypes might increase proliferation after low-dose irradiation.
Source: Clinical Oral Investigations - Category: Dentistry Source Type: research
Anti-Trop2 blockade enhances the therapeutic efficacy of ErbB3 inhibition in head and neck squamous cell carcinoma, Published online: 05 January 2018; doi:10.1038/s41419-017-0029-0Anti-Trop2 blockade enhances the therapeutic efficacy of ErbB3 inhibition in head and neck squamous cell carcinoma
Source: Cell death and disease - Category: Internal Medicine Authors: Source Type: research
Treatment options for patients with platinum-refractory, recurrent, metastatic head and neck squamous cell carcinoma (HNSCC) are limited, and prognosis is poor. Nivolumab (Opdivo) has been approved by the US Food and Drug Administration (FDA) for the treatment of patients with recurrent or metastatic HNSCC who have disease progression on or after platinum-based therapy. Recently, in patients with metastatic malignant melanoma a significant improvement of outcome and response was achieved with the combination of ipilimumab (CTLA4 antibody) and the programmed death (PD)-1 inhibitor nivolumab compared with monotherapy. Based ...
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
This article is protected by copyright. All rights reserved.
Source: International Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Article Source Type: research
Condition:   Head and Neck Squamous Cell Carcinoma Interventions:   Drug: Palbociclib;   Drug: Cetuximab;   Drug: Cisplatin;   Radiation: Intensity-Modulated Radiation Therapy;   Procedure: Tumor biopsy;   Procedure: Peripheral blood draw;   Other: European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 Sponsors:   Washington University School of Medicine;   Pfizer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | HNSCC | Pathology | Skin Cancer | Squamous Cell Carcinoma